Product logins

Find logins to all Clarivate products below.


Prostate Cancer | Treatment Sequencing | EU5 | 2017

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.

Related Market Assessment Reports

Report
Prostate Cancer – Current Treatment – Current Treatment: Physician Insights – Prostate Cancer (US)
Hormonal therapy remains the foundation of drug treatment for prostate cancer across all patient populations, with ADT serving as the universal backbone. ARPIs—enzalutamide, apalutamide, and…
Report
Prostate Cancer – Current Treatment – Treatment Sequencing – Prostate Cancer (US)
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
Report
Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-…
Report
Prostate Cancer | Disease Landscape & Forecast | G7 | 2025
Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-…
Report
Prostate Cancer – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts of key prostate cancer patient populations, covering 171 countries and more…